Bristol Myers Squibb (BMY) earnings Q1 2024
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
Stay updated with breaking news from Biotechnology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
Agri-Pulse is a trusted source in Washington, D.C., with the largest editorial team focused on food, fuel, fiber and farm policy coverage. Agri-Pulse presents a balanced perspective on a wide variety of issues.
For the first time, some Medicare beneficiaries will be able to access Novo Nordisk's Wegovy without having to shoulder the total monthly price tag.
Roche lowered its 2024 growth outlook in February as it continues to confront a drop-off in demand for its Covid-19 products and a number of its cancer drugs.